Concepedia

Evaluating the Clinical Effectiveness and Safety of Semaglutide in Individuals with Uncontrolled Type 2 Diabetes. Real-World Evidence from Saudi Arabia: The Observational, Multicenter, 15-Month EVOLUTION Study

Abdulrahman Alsheikh, Ali Alshehri, Saad Alzahrani, Anwar A. Jammah, Fahad Alqahtani, Metib Alotaibi, Raed Aldahash, Amani Alhozali, Fahad Alsabaan, Mohammed Almehthel,

Diabetes Therapy · 2023 · 14 citations · 27 references

DOIFull text

Open access

Abstract

Semaglutide, administered either by SC injection or orally, provided substantial glycemic and weight-loss benefits in adults with T2DM.

References

27

Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition

Pouya Saeedi, Inga Petersohn, Belma Malanda et al. · Diabetes Research and Clinical Practice · 2019 · 10K citations

, , +8

Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide

Jesper Lau, Paw Bloch, Lauge Schäffer et al. · Journal of Medicinal Chemistry · 2015 · 959 citations · Full text

, , +19

The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss

Anna Secher, Jacob Jelsing, Arian F. Baquero et al. · Journal of Clinical Investigation · 2014 · 884 citations · Full text

, , +17

Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial

Richard E. Pratley, Vanita R. Aroda, Ildiko Lingvay et al. · The Lancet Diabetes & Endocrinology · 2018 · 714 citations

, , +9

Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial

Christopher Sorli, Shin‐ichi Harashima, George Tsoukas et al. · The Lancet Diabetes & Endocrinology · 2017 · 648 citations · Full text

, , +7